All In Biotech

Drug Trial Radar · NCT07626034

A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398

An Open-label Positron Emission Tomography (PET) Study to Evaluate Brain Dopamine D2 and D3 Receptor Occupancy by SIPI6398 in Healthy Volunteers and Patients With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Yale University
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.

Conditions

  • Schizophrenia Disorder

Interventions

  • SIPI6398 TabletsDrug

    SIPI6398 Tablets will be administered orally once daily for 7 consecutive days to healthy volunteers or for 8 consecutive days to patients with schizophrenia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Brain dopamine D2 and D3 receptor occupancy following oral doses as measured by PET.Time frame: Baseline and post-dose, up to 9 days for healthy volunteers and up to 8 days for schizophrenia patients

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.